结肠癌治疗的发展研究
摘要
对肿瘤的标准诊断通常基于应用细胞毒性药物，放疗，化疗以及术后，靶向药物在结肠癌的化疗用药和术 前化疗过程中起着关键性作用，能够延长结肠癌病人的生存期，从而改善他们的生存质量。本研究概括了结肠癌靶 向药物疗法的主要靶向药物，及其新型治疗药物的研究进展。参考
[1] 丁志海，靶向药物治疗转移性结肠癌的研究进
展 %J 医疗装备 .2018.31（06）：p.203-204.
[2] 杨波，et al.，结肠癌及其分型的靶分子修饰递
送药物的研究进展 %J 中国药房 .2019.30（18）：p.2577-
2582.
[3]Yamagishi, H., et al., Molecular pathogenesis of
sporadic colorectal cancers. Chin J Cancer, 2016. 35: p. 4.
[4]Schell, M.J., et al., A multigene mutation classification
of 468 colorectal cancers reveals a prognostic role for APC. Nat
Commun, 2016. 7: p. 11743.
[5]Pandurangan, A.K., et al., Colorectal carcinogenesis:
Insights into the cell death and signal transduction pathways: A
review. World J Gastrointest Oncol, 2018. 10(9): p. 244-259.
[6] 向琳 and 彭金兰，抗肿瘤新药——贝伐单抗 %J 医
药导报 %J HERALD OF MEDICINE. 2006. 25(10): p. 1087-
1088.
[7]Garcia, J., et al., Bevacizumab (Avastin®) in cancer
treatment: A review of 15 years of clinical experience and
future outlook. Cancer Treatment Reviews, 2020. 86: p.
102017.
[8]Chen, M., et al., The epidermal growth factor receptor
(EGFR) is proteolytically modified by the Matriptase-Prostasin
serine protease cascade in cultured epithelial cells. Biochim
Biophys Acta, 2008. 1783(5): p. 896-903.
[9]Cerea, G., et al., Cetuximab for treatment of metastatic
colorectal cancer. Annals of Oncology, 2006. 17: p. vii66-
vii67.
[10]Chen, R., et al., Modulation of the tumour
microenvironment in hepatocellular carcinoma by tyrosine
kinase inhibitors: from modulation to combination therapy
targeting the microenvironment. Cancer Cell Int, 2022. 22(1): p.
73.
[11]Zhao, P., et al., Dual-targeting biomimetic
delivery for anti-glioma activity via remodeling the tumor
microenvironment and directing macrophage-mediated
immunotherapy. Chem Sci, 2018. 9(10): p. 2674-2689.
[12] 王 嘉 源 and 董 卫 国， 结 肠 癌 靶 向 治 疗 研 究
Targeted therapy for colon cancer %J 胃肠病学和肝病学杂
志 %J Chinese Journal of Gastroenterology and Hepatology.
2020. 29(7): p. 721-725.
